We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 5,783

PTAB institutes Kyle Bass Lialda patent IPR
  • Foley & Lardner LLP
  • USA
  • October 13 2015

After filing over thirty petitions for Inter Partes Review of Orange Book-listed patents for various drugs, Kyle Bass and his Coalition for

High Court of Australia unanimously decides that isolated genetic material is not patentable in Australia
  • DLA Piper LLP
  • Australia
  • October 12 2015

In D'Arcy v Myriad Genetics Inc 2015 HCA 35 (D'Arcy v Myriad) the High Court of Australia has unanimously held (by way of three separate judgments:

Large damages payment looms for generic manufacturers in relation to Escitalopram
  • Shelston IP
  • Australia
  • October 12 2015

The Full Federal Court of Australia has dismissed an appeal by Alphapharm and others against the Federal Court decision to allow a patent term

Competition law as panacea for high prices?
  • Bristows LLP
  • European Union, India, United Kingdom
  • October 12 2015

It seems that the CMA's opening of an investigation into Pfizer Flynn (which we discussed here) may not be the only pending competition case on

Isolated nucleic acids not patentable in Australia
  • Spruson & Ferguson
  • Australia
  • October 9 2015

The High Court’s decision marks a dramatic departure from the Australian Parliament’s position on “gene patents” in recent years. The Act only

CJEU paves the way for longer SPC terms: the Seattle Genetics case
  • CMS Derks Star Busmann
  • European Union
  • October 9 2015

On 6 October 2015, the EU Court of Justice (“CJEU”) held that the date a centralised marketing authorization (“MA”) holder receives notification that

High Court of Australia determines isolated BRCA1 gene not patentable in Australia
  • Herbert Smith Freehills LLP
  • Australia
  • October 9 2015

The High Court of Australia has unanimously overturned previous decisions from lower courts and has held that certain claims to Myriad's patent for

High Court of Australia finds that isolated genetic material is not patentable subject matter
  • Bird & Bird
  • Australia
  • October 9 2015

On 7 October 2015, the High Court of Australia (High Court) handed down its unanimous decision in D'Arcy v Myriad Genetics Inc, finding that an

The Trans-Pacific partnership: changes for patents and pharmaceuticals?
  • Gowling Lafleur Henderson LLP
  • Asia-Pacific, Canada
  • October 8 2015

Changes may be on the horizon for Canada’s legal and regulatory regime for patents and pharmaceuticals. Included in the Trans-Pacific Partnership

High Court of Australia goes cold on patentability of isolated nucleic acid
  • Clayton Utz
  • Australia
  • October 8 2015

In a highly anticipated decision, the High Court of Australia has unanimously determined that an isolated nucleic acid (coding for mutations in the